Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL
Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: onclive.com
Liso Cel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Liso Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Liso Cel Today - Breaking & Trending Today
Current Treatment Options in Third-line MCL
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Source: onclive.com
Sequencing Therapies in the Third-Line and Beyond Setting for MCL
A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Source: onclive.com
Choosing CAR T-cells as Third-line and Beyond Therapy for FL
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
Source: onclive.com
ASH Abstracts Showcase Effective Treatments for MM, CLL, FL
Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Source: ajmc.com